MatthewRCooperbergMDMPH, FACS

Surgical Oncology

Helen Diller Family Professor, Department of Urology, UCSF

Dr. Cooperberg is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

Office
1825 4th St
San Francisco, CA 94143
Phone+1 415-476-4616

Fax+1 415-514-6195

CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012
Fellow (FACS) American College of Surgeons

Pioneering Advances in Care and Education (PACE) Start of enrollment: 2018 Jul 19
Completed
Not Applicable

PubMed

Determining Long-term Prostate Cancer Outcomes for Active Surveillance Patients Without Early Disease Progression: Implications for Slowing or Stopping Surveillance.
Kevin Shee, James Nie, Janet E Cowan, Lufan Wang, Samuel L Washington 3rd
European Urology Oncology. 2025-04-01
Androgen Receptor Inhibition Increases MHC Class I Expression and Improves Immune Response in Prostate Cancer.
Lisa N Chesner, Fanny Polesso, Julie N Graff, Jessica E Hawley, Alexis K Smith
Cancer Discovery. 2025-03-03
1 citations
When is prostate cancer really cancer?
Matthew R Cooperberg, Avery E Braun, Alejandro Berlin, Adam S Kibel, Scott E Eggener
Journal of the National Cancer Institute. 2025-03-01

Journal Articles

Regional Variation in Active Surveillance for Low-Risk Prostate Cancer in the US
Peter E Lonergan, Matthew R Cooperberg, JAMA Network Open
Development and Validation of a Clinical Prognostic Stage Group System for Nonmetastatic Prostate Cancer Using Disease-Specific Mortality Results from the Internationa...
Michael J Zelefsky, Matthew R Cooperberg, Brian J Davis, Eric M Horwitz, Martha K Terris, Christopher L Amling, Christopher J Kane, Curtiland Deville, Theodore L Dewee..., JAMA Oncology
Tailoring Intensity of Active Surveillance for Low-Risk Prostate Cancer Based on Individualized Prediction of Risk Stability
Matthew R Cooperberg, Atreya Dash, JAMA Oncology
First-in-Human Phase I Study of CTT1057, a Novel 18F Labeled Imaging Agent with Phosphoramidate Core Targeting Prostate Specific Membrane Antigen in Prostate Cancer
Spencer C Behr, Hao G Nguyen, Thomas A Hope, Kirsten L Greene, Matthew R Cooperberg, Robert R Flavell, Eric J Small, Peter R Carroll, Journal of Nuclear Medicine
Obesity, Risk of Biochemical Recurrence, and PSADT After Radical Prostatectomy: Results from the SEARCH Database
Matthew R Cooperberg, Christopher L Amling, Christopher J Kane, BJU International
Join now to see all

Tailoring Intensity of Active Surveillance for Low-Risk Prostate Cancer Based on Individualized Prediction of Risk StabilityAugust 2020
The Diverse Genomic Landscape of Clinically Low-Risk Prostate CancerMay 2018
A Contemporary Prostate Biopsy Risk Calculator Based on Multiple Heterogeneous CohortsMay 2018
Effect of Prostate Cancer Severity on Functional Outcomes After Localized Treatment: Comparative Effectiveness Analysis of Surgery and Radiation Study ResultsFebruary 2018
How Should a Man with Prostate Cancer Choose His Surgeon?February 2018
Join now to see all

Have Anti-PSA Screening Guidelines Upped Prostate Cancer Incidence and Mortality?February 10th, 2025
California Sees Alarming Rise in Rates of Advanced Prostate Cancer Since Routine Screening StoppedFebruary 3rd, 2025
Let's Not Call It CancerJanuary 9th, 2025
Join now to see all

Multimodality spatial analysis in prostate cancer to improve prognostic estimation and cast light into the black box of pathology artificial intelligence algorithmsUNIVERSITY OF CALIFORNIA, SAN FRANCISCO2025–2029